• Open Access

Enabling Innovative Translational Research in Acute Kidney Injury

Authors

  • Abolfazl Zarjou M.D.,

    1. Department of Medicine, Division of Nephrology, Nephrology Research and Training Center and Center for Free Radical Biology, University of Alabama at Birmingham, Birmingham, Alabama, USA
    Search for more papers by this author
  • Paul W. Sanders M.D.,

    1. Department of Medicine, Division of Nephrology, Nephrology Research and Training Center and Center for Free Radical Biology, University of Alabama at Birmingham, Birmingham, Alabama, USA
    2. Department of Veterans Affairs Medical Center, Birmingham, Alabama, USA
    Search for more papers by this author
  • Ravindra L. Mehta M.D.,

    1. Internal Medicine, Division of Nephrology, University of California, San Diego, California, USA.
    Search for more papers by this author
  • Anupam Agarwal M.D.

    Corresponding author
    1. Department of Medicine, Division of Nephrology, Nephrology Research and Training Center and Center for Free Radical Biology, University of Alabama at Birmingham, Birmingham, Alabama, USA
    2. Department of Veterans Affairs Medical Center, Birmingham, Alabama, USA
    Search for more papers by this author

A Agarwal (agarwal@uab.edu)

Abstract

Acute kidney injury (AKI) is a common, heterogeneous, and detrimental clinical condition that has significant attributable morbidity and mortality. Despite major advances in understanding the epidemiology, pathogenesis, and outcomes of AKI, preventive measures remain inadequate and therapeutic approaches (except for renal replacement therapy) have largely proven futile so far. Critical to the process of designing rational therapies is translational research, which involves the transition between the basic research discoveries and everyday clinical applications to prevent, diagnose, and treat human diseases. Progress in innovative approaches has been hampered due in part to the reliance on functional markers (serum creatinine and blood urea nitrogen) that are neither sensitive nor specific to diagnose AKI. This limitation has created a great deal of interest and intense investigation to identify a “troponin-like marker” that would facilitate recognition of AKI and allow for timely implementation of the precise therapeutic agent. The other major obstacle in this field is the diverse and complex nature of AKI that involves multiple independent and overlapping pathways, making it difficult to cure AKI with a single approach. In this review, we will summarize the advances, ongoing studies, and future perspectives in the field of translational research of AKI. Clin Trans Sci 2012; Volume 5: 93–101

Ancillary